Please login to the form below

sitagliptin

This page shows the latest sitagliptin news and features for those working in and with pharma, biotech and healthcare.

Reference price bill tabled in US House and Senate

savings for several other drugs including Pfizer’s hormone replacement therapy Premarin (conjugated oestrogens), Merck &Co’s Januvia (sitagliptin) for diabetes, and Astellas/Pfizer’s prostate cancer therapy Xtandi (enzalutamide).

Latest news

Novo’s diabetes pill defeats Merck’s Januvia in trial

achieved the target HbA1c level – 7% or lower – compared to 28% of those treated with sitagliptin after 52 weeks of treatment. ... The drug also hit the mark in the obesity setting, with patients achieving statistically significant and superior
FDA’s year-end approvals take annual tally to 46

Merck and Pfizer picked up an FDA approval for SGLT2 inhibitor Steglatro (ertugliflozin) and combinations Steglujan (ertugliflozin and sitagliptin) and Segluromet (ertugliflozin and metformin) for use in adults with type 2
FDA panel backs CV claims for Novo Nordisk's Victoza

Merck &Co failed to win FDA approval for a similar claim for its DPP-4 inhibitor Januvia (sitagliptin) in April.
FDA won't add outcomes data to Januvia label

The US regulator has sent the pharma company a complete response letter for DPP-4 inhibitor Januvia (sitagliptin) and combination product Janumet (sitagliptin plus metformin) - along with extended release formulations - saying
Merck & Co and Pfizer take aim at diabetes with trio of new drugs

The marketing applications – filed in the US and EU – cover ertugliflozin as a monotherapy, a fixed-dose combination of ertugliflozin and Januvia (sitagliptin), and a fixed-dose combination of the SGLT2

More from news
Approximately 8 fully matching, plus 83 partially matching documents found.

Latest Intelligence

Market dynamics, marketing and analytics

The dotted horizontal line denotes market growth. The vertical dotted line indicates market leadership where Sitagliptin (Januvia) is the clear winner that is no longer growing at the speed of the
Interview: Christopher Boulton, AstraZeneca

sitagliptin) and Bristol-Myers Squibb (BMS), the original marketers of diabetes standard metformin under the brand name Glucophage.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Senior Medical Writer: Salary TBC

Project Manager/ Account Manager: Salary TBC

AD – Corporate Comms/ Public Affairs/ B2B – Healthcare Focus: Salary TBC

Senior Medical Writer: Up to £50, 000 with Benefits

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Senior Planner – Healthcare Advertising – New Role: Salary TBC

PR Director – Health & Wellbeing – Mat Cover (4 days a week)...: Salary TBC

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Account Director, Medical Education: Salary TBC

Account Director, Healthcare Marketing Agency: Salary TBC

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Account/ Project Director – Medical Affairs – Surrey: Salary TBC

Senior Medical Writer: Great salary and benefits

Project/ Events Manager – Medical Education and Events Agency: Salary TBC

Digital Account Director: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

The importance of co-creation with patients: Overcoming the barriers...
Three billboards on the road to multichannel: Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence: Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....